Bristol-Myers, Pfizer Report Investigational Eliquis Data - Quick Facts

(RTTNews) - Bristol-Myers Squibb Company (BMY) and Pfizer Inc. (PFE) reported findings from EMANATE, a Phase 4 clinical trial. The descriptive, randomized, open-label trial explored the safety and efficacy of apixaban 5 mg twice daily vs. standard of care. The company said the results showed that, in the intent-to-treat population, there were no strokes or systemic emboli in the Eliquis group compared to six strokes and no systemic emboli in the standard of care group.

In the safety analysis population, there were numerically fewer major bleeding events in the apixaban treatment group than those randomly assigned to standard of care, and numerically fewer clinically relevant non-major bleeding events in the apixaban treatment group than those randomly assigned to standard of care. Eliquis increased the risk of bleeding and can cause serious, potentially fatal, bleeding. There were two deaths in the Eliquis group and one in the standard of care group.